Nyenta.com

Menu
  • Home
  • Business
  • Financial
  • Education
  • Technology
  • Music
  • Books
  • Entertainment
  • Health
Menu

New Drug Application to the FDA for the Treatment of Suicidal Depression that Affects 13+ Million Americans Each Year: NRx Pharma: Stock Symbol:NRXP
Nyenta.com/10299737

Trending...
  • Pyro Marketing Opens New Digital Marketing Company to Power Growth for Fitness and Ecommerce Brands
  • Beijing Review: ChASC5 Bridging Hearts Across The Pacific
  • BMCC Tribeca PAC Presents New Season of Music, Theater & Family Fun
NRXP NASDAQ NASDAQ NRXP NRXP 2 NRXP Chief Business Officer NRXP 5 Corporate Ads
$NRXP: Completion of NDA Filing Expected in First Quarter of 2025

MIAMI - Nyenta -- Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain.

Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression

Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC).

Plans to Participate in J.P. Morgan Healthcare Conference on January 13-16, 2025, in San Francisco, CA.

Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials."

Featured on Psychiatrist.com: "How NRx Could Upend the Fight Against Depression and Suicide."


NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain

NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

Intravenous ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product; the only treatment currently approved by the FDA is electroconvulsive therapy (ECT).  According to the CDC, 3.8 million Americans make a plan for suicide each year.  This represents a $3-5 billion market at expected pricing.  Based on the data in the trials referenced above, the Company's regulatory counsel encouraged the Company to file an NDA for suicidal depression for NRX-100.

More on Nyenta.com
  • $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: FL, STRM, TXNM, and CTLP
  • Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
  • Happi Coffee Launches with a Mission to Bring Freshness, Simplicity, and Intention to Your Daily Cup
  • SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Krispy Kreme
  • Local firm Launches QuickBooks Support to Help Small Businesses Streamline Finances and Boost Growth

Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression

On December 30th NRXP announced the transmission of first section of its New Drug Application (NDA) for NRX-100 (ketamine) for electronic filing with the U.S. Food & Drug Administration (FDA). NRX-100 was initially granted Fast Track Designation in 2017 for use in combination with NRX-101 (D-cycloserine/lurasidone) for treatment of suicidal bipolar depression. The Company is now seeking to expand the indication to include Suicidal Ideation in Major Depressive Disorder and other forms of depression, based on data from NIH- and European Government-funded trials that have been summarized on the NRXP website.

While assembly of the clinical data sections is being completed, FDA has asked the Company to submit the 1800-page manufacturing section (Module 3) of the NDA to enable immediate review prior to submission of final efficacy data and other sections of the NDA expected in the first quarter of 2025.

The NRx presentation of ketamine differs from the form of ketamine used in anesthesia in that it contains no potentially toxic preservatives and utilizes diversion-resistant packaging to enhance the traceability of a medicine known to have abuse potential.

Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials"

On November 25th NRXP announced the publication of a paper by Sapko, et. al. in the peer-reviewed American Journal of Clinical Psychopharmacology.  The paper, entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials,"1 reported on the impact of a comprehensive program developed by NRx Pharmaceuticals to enhance reliability in psychometric ratings that are key to drug approval. Registration trials of drugs for depression and related conditions frequently fail because of unexpected statistical variability across study sites. NRx developed a methodology for training and monitoring the performance of the study site raters, whose measurements are key to the success or failure of all clinical trials of antidepressant drugs. This approach resulted in an unprecedented level of agreement (3 points or better on a 60 point scale) compared to prior industry practices.

More on Nyenta.com
  • KCON LA 2025, 106.3 RAIN FM 'Take Over' Special Event
  • Natcast Celebrates Grand Opening of NSTC EUV Accelerator at NY CREATES' Albany NanoTech Complex, One of Three NSTC Flagship Semiconductor R&D Facilities Across the Country
  • Don't Let a Lawsuit Take Away Everything: Attorney Blake Harris Joins Tom Hegna on "Financial Freedom with Tom Hegna"
  • New Book Executive One Chronicles the Visionary Leadership of Ernest E. Middleton, PhD
  • What do a Police Officer, a Retiree, and an 8-Year-Old Girl have in Common?

In the NRX-101 study, trial concordance, as defined by no more than 3 points of disagreement between site raters and central raters, was seen in 94.5% of ratings, where standard industry practice was to accept substantially higher variance (i.e. up to 6 points of disagreement) between study site raters and central raters.2 Accepting higher variance entails recruiting many more participants to achieve statistical significance with substantially higher study costs and risks of failure. NRXP will be using this improved methodology in future drug development, and clinical trials conducted within its network of HOPE clinics.

NRx Pharmaceuticals, Inc. Featured on Psychiatrist.com: "How NRx Could Upend the Fight Against Depression and Suicide"

The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found at this direct link: https://www.psychiatrist.com/news/how-nrx-could-upend-the-fight-against-depression-and-suicide/.

For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/

Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Company Website: https://www.nrxpharma.com/
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Home Country: United States

Disclaimer and Disclosure: www.corporateads.com

Contact
Corporate Ads
***@gmail.com


Source: Corporate Ads
Filed Under: Business, Health, Financial

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on Nyenta.com
  • The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
  • Momentum Commerce Tracking of Amazon US Prime Day Sales Shows +165% Increase on Day 3, Path to Year-over-Year Growth
  • The Sessions Studios Secures $300 Million Commitment to Launch World-Class Studio and 15-Film Global Slate
  • Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
  • Olson's Walk-Off Hit Gives N.L. All-Star Game Triumph In Strat-O-Matic Simulation
  • Beijing Review: ChASC5 Bridging Hearts Across The Pacific
  • Josh and Heidi Follow Up the Much Anticipated and Successful Launch of the "Spreading the Good BUZZ" Podcast with a Personal Request
  • Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market
  • Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
  • Easton & Easton, LLP Files Suit Against The Dwelling Place Anaheim & Vineyard USA Over Abuse Allegations
  • AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
  • Rod Joseph Honored at First International Day of Hope in New York City
  • Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
  • Tronox Announces Dates for Second Quarter 2025 Earnings Release & Webcast Conference Call
  • Colbert Packaging Announces WBENC Recognition
  • Non-Profit Pay Away Announces Support to Boys & Girls Clubs of America for Back-to-School Giving
  • RBLP Leadership Certifications is authorizing new Training Partners in New York
  • BMCC Tribeca PAC Presents New Season of Music, Theater & Family Fun
  • CPAmerica welcomes Trullion as a new Preferred Provider, supporting modernized accounting processes
  • The Fabulous Wines of Provence, France

Popular on Nyenta

  • IPTVGANG Crowned Best IPTV Service Provider of 2025 by Overwhelming User Acclaim - 146
  • TEAMSTERS REQUEST UPS DATA ON HEAT PROTECTIONS, OVERTIME VIOLATIONS, STAFFING - 130
  • LOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo Pharma USA - English APAC - English Japan - Japanese USA - English - 127
  • ASI Accelerates iMISĀ® Innovation by Acquiring CSI's Product Suite and Expert Team - 122
  • Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI - 113
  • Exciting News: Pivotal Health Solutions Acquires Revolutionary Portable Parallel Bars - 111
  • SupplyHouse Named One of Fortune's Best Workplaces in New York in 2025 - 108
  • Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT - 108
  • Recovery Arts Project and Bigvision announce partnership to combat addiction through the arts
  • New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient

Similar on Nyenta

  • SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
  • Eshbal Signs Additional Binding Agreement and Strengthens U.S. Leadership Team
  • $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: FL, STRM, TXNM, and CTLP
  • Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
  • SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Krispy Kreme
  • Local firm Launches QuickBooks Support to Help Small Businesses Streamline Finances and Boost Growth
  • Natcast Celebrates Grand Opening of NSTC EUV Accelerator at NY CREATES' Albany NanoTech Complex, One of Three NSTC Flagship Semiconductor R&D Facilities Across the Country
  • Don't Let a Lawsuit Take Away Everything: Attorney Blake Harris Joins Tom Hegna on "Financial Freedom with Tom Hegna"
  • The Citizens Commission on Human Rights Annual Purple Heart Day Event will be Hosted at the Historic Fort Harrison
  • Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
Copyright © 2025 nyenta.com | Terms of Service | Privacy Policy | Contribute | Contact Us